Subject(s)
Humans , Male , Female , Epidemiology , Smoking Prevention , Smoking , Tobacco Use Disorder , Spain , Health SurveysABSTRACT
Introducción.La irrupción de los cigarrillos electrónicos (e-cig) y nuevos productos de consumo de tabaco ha supuesto un desfase en el conocimiento del tabaquismo entre el personal sanitario. Los escasos estudios sobre su eficacia y la intromisión de la industria tabaquera no ayudan a dirimir la controversiaexistente entre su uso como ayuda para la cesación/reducción de daños frente a su asimilación al resto de labores del tabaco. Sujetos y métodos: Se realiza una encuesta dirigida a personal sanitario a nivel de toda España tratando de constatar el conocimiento sobre los e-cig, sus potenciales daños, empleo en la clínica, papel de la industria y legislación actual en España. Para ello, a través de un entorno online, se distribuye un cuestionario a responder entre los días 12 y 26 de agosto de 2019. Resultados: Se reciben 266 encuestas, la mayoría de mujeres (3:1), médicas (73,3 %) y con 11 años o más de experiencia (54,5%). Un 30,5% no conoce ningún tipo de e-cig y el 78,6 % no se siente capacitado ni para informar ni para tratar a los consumidores. Ven riesgos de cronificar la cesación (77,8%) y normalizarel consumo de nicotina en lugares ya libres de humo (62,8%), aunque hasta el 44% cree que pueden tenerun papel como herramienta de cesación en determinados pacientes, siendo asumida la ausencia de estudios que los avalen (38,3%). El 62% ve una actitud engañosa de las tabaqueras y el 51,9% en su regulación como productos de consumo sin existir una legislaciónespecífica. Comparadas las respuestas entre profesionales médicos y no médicos, por años de experiencia ygrupos de edad, destacan diferencias estadísticamente significativas (p < 0,05) en la percepción de daños,el papel de las tabaqueras y en el conocimiento más específico de los dispositivos entre el personal másjoven y/o con menos años de experiencia. (AU)
Introduction: The appearance of electronic cigarettes (E-cig) and new products of use of tobacco have entailed a lag in the knowledge of smoking habit among health care personnel. The scarce studies on its efficacy and the meddling of the tobacco industry have not helped to solve the controversy existing between its use as an aid for smoking cessation/reduction of harm against its assimilation to the remaining tobacco products.Subjects and methods: A survey addressed to the health care personnel in Spain was carried out. It aimed to determine the knowledge on the E-cig, their potential harm, use in the clinical practice, role of the industry and current legislation in Spain. To do so, a questionnaire to be answered was distributed onlinebetween 12 and 26 of August 2019. Results: A total of 266 surveys were received, most of which were from women (3:1), doctors (73.3%) and with 11 years of more of experience (54.5%). Of these, 30.5 % did not know any type of E-cig and 78.6 % did not feel qualified to inform or to treat the users. They see risks of the smoking cessation becoming chronic (77.8%) and making the use of nicotine normal in sites that are already smoke free (62.8%), although up to 44% believe that they canhave a role as a tool to quit smoking in some patients, the absence of studies that support being assumed (38.3%). 62% consider that the tobacco companies have a misleading attitude and 51.9% in their regulation as products of use without the existence of specific legislation. When comparing the answersbetween the medical and non-medical professionals, there are statistically significant differences by years of experience and age groups (p < 0.05) in the perception of harm, the role of the tobacco companies and in the most specific knowledge of the devices among the younger personnel and/or those with fewer years of experience. (AU)
Subject(s)
Humans , Electronic Nicotine Delivery Systems/statistics & numerical data , Tobacco Use Cessation Devices/statistics & numerical data , Tobacco Use Cessation Devices/trends , Health Personnel/statistics & numerical data , Health Personnel/trends , Surveys and Questionnaires , Spain , Tobacco Use Disorder/prevention & control , Tobacco Use Disorder/therapyABSTRACT
Introducción. La relación entre la enfermedad pulmonar obstructiva crónica (EPOC) y la incidencia global de cáncer es poco conocida. El objetivo del estudio fue analizar la incidencia de cáncer (tanto de localización pulmonar como extrapulmonar) en pacientes con EPOC en seguimiento en una consulta ambulatoria especializada, así como valorar su relación con el grado de obstrucción al flujo aéreo. Metodología. Estudio observacional prospectivo de una cohorte de 308 pacientes con EPOC en seguimiento en consultas ambulatorias de neumología durante el periodo comprendido entre enero de 2012 y diciembre de 2015. Las neoplasias diagnosticadas en este periodo se dividieron en pulmonares y extrapulmonares. Resultados. Las tasas de incidencia global de cáncer, de cáncer de pulmón (CP) y de cáncer extrapulmonar fueron de 10,3, 3,4 y 7,3 casos por 1.000 pacientes EPOC-año, respectivamente. Los tumores más frecuentes fueron el CP (31%), los del tracto genitourinario (29%) y digestivo (21%). Los estadios leve-moderado (gradosI-II de la GOLD 2009) y el incremento del índice paquetes-año (IPA) se relacionaron con un aumento en la aparición de neoplasias con un odds ratio (OR) de 2,16 (intervalo de confianza al 95% [IC95%]: 1,087-4,309; p=0,026) y 1,01 (IC95%:1,002-1,031; p=0,023), respectivamente. Conclusión. La incidencia de cáncer de localización extrapulmonar en pacientes con EPOC duplica a la de CP. Los estadiosI-II de la GOLD 2009 y el IPA se relacionan de forma significativa con la aparición de neoplasias (AU)
Introduction. The relationship between chronic obstructive pulmonary disease (COPD) and the overall incidence of cancer is poorly understood. The aim of this study was to analyse the incidence of cancer (pulmonary or extrapulmonary) in patients with COPD during follow-up in a specialised outpatient unit, as well as to assess its relationship with the degree of airflow obstruction. Methodology. A prospective observational study was conducted with a cohort of 308 patients with COPD in pulmonology outpatient follow-up consultations from January 2012 to December 2015. The diagnosed malignancies during this period were divided into pulmonary and extrapulmonary. Results. The overall incidence rate of cancer, lung cancer and extrapulmonary cancer were 10.3, 3.4 and 7.3 cases per 1,000 patients with COPD per year, respectively. The most common cancers were lung cancer (31%), genitourinary tract cancer (29%) and gastrointestinal cancer (21%). Mild-moderate stages (gradeI-II of the 2009 GOLD classification) and the increase in the pack-year index (PYI) were related to an increase in the onset of malignancies, with an odds ratio (OR) of 2.16 (95% confidence interval [95% CI]: 1.087-4.309; P=.026) and 1.01 (95% CI: 1.002-1.031; P=.023), respectively. Conclusion. The incidence of extrapulmonary cancer in patients with COPD was twice that of lung cancer; stagesI-II of the 2009 GOLD classification and the PYI were significantly related to the onset of malignancies (AU)
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Pulmonary Disease, Chronic Obstructive/complications , Neoplasms/epidemiology , Ambulatory Care/statistics & numerical data , Risk Factors , Smoking/epidemiology , Odds Ratio , Confidence Intervals , Prospective Studies , 28599ABSTRACT
INTRODUCTION: The relationship between chronic obstructive pulmonary disease (COPD) and the overall incidence of cancer is poorly understood. The aim of this study was to analyse the incidence of cancer (pulmonary or extrapulmonary) in patients with COPD during follow-up in a specialised outpatient unit, as well as to assess its relationship with the degree of airflow obstruction. METHODOLOGY: A prospective observational study was conducted with a cohort of 308 patients with COPD in pulmonology outpatient follow-up consultations from January 2012 to December 2015. The diagnosed malignancies during this period were divided into pulmonary and extrapulmonary. RESULTS: The overall incidence rate of cancer, lung cancer and extrapulmonary cancer were 10.3, 3.4 and 7.3 cases per 1,000 patients with COPD per year, respectively. The most common cancers were lung cancer (31%), genitourinary tract cancer (29%) and gastrointestinal cancer (21%). Mild-moderate stages (gradeI-II of the 2009 GOLD classification) and the increase in the pack-year index (PYI) were related to an increase in the onset of malignancies, with an odds ratio (OR) of 2.16 (95% confidence interval [95% CI]: 1.087-4.309; P=.026) and 1.01 (95% CI: 1.002-1.031; P=.023), respectively. CONCLUSION: The incidence of extrapulmonary cancer in patients with COPD was twice that of lung cancer; stagesI-II of the 2009 GOLD classification and the PYI were significantly related to the onset of malignancies.
ABSTRACT
No disponible
Subject(s)
Female , Middle Aged , Humans , Granuloma/diagnosis , Lung Diseases/diagnosisABSTRACT
No disponible
